San Diego Confirmed Medetomidine in Its Drug Supply. Its Surveillance Has Recorded No Cases.
San Diego County confirmed the veterinary sedative medetomidine in its drug supply on Oct. 29 — while its surveillance recorded zero cases. Here is why.

On October 29, San Diego County Public Health Services sent a two-page advisory to the region's physicians, laboratorians and public health staff. The title left no room: Medetomidine in the San Diego County Drug Supply.
Medetomidine is a veterinary sedative — a potent alpha-2 adrenergic agonist approved to sedate dogs, with no approved human use. On the street it travels as "rhino tranq," "mede" or "dex." It is almost never sold on its own: it appears as an adulterant inside illicitly manufactured fentanyl, deepening and prolonging sedation in ways naloxone cannot touch.
The advisory contains a second sentence that matters as much as the first, though it reads like an absence rather than a finding. The county writes that its syndromic surveillance "has not identified potential cases of medetomidine in 2025-2026." The county Medical Examiner's Office told News 8 there had been no deaths related to it.
So the drug is confirmed in the supply, and the health record shows nothing. Both are true at once, and understanding why is the most useful thing a family can take from this week.
What the county actually found
The advisory is short and specific about its own limits. Medetomidine, it says, "is increasingly being found in the illegal drug supply, including in San Diego County," and has "recently been detected in California including San Diego County." The detections came from two routes: drug checking run by syringe services organizations, and testing by law enforcement. The county is candid that this tells it less than a family might assume — it says it is difficult to determine how much medetomidine is actually circulating locally.
What the county can say with confidence is what the drug does. Medetomidine toxicity "can mimic opioid overdose and can intensify sedative effects of opioids," and its effects "are not reversed by naloxone." That reshapes the first five minutes of an overdose: naloxone is still required, because fentanyl is present in most medetomidine cases, but a reversal that restores breathing may leave the person deeply asleep.
Why a confirmed detection and a zero can both be true
Four documented mechanisms explain the gap.
The lab threshold is above the fatal range. The county states plainly that clinical laboratory testing "may underestimate the true presence of medetomidine, as the concentration required for detection often exceeds the levels reported in fatal medetomidine overdose cases." A negative hospital toxicology screen is not an all-clear.
Until last month, there was no code to count it with. The FY2027 ICD-10-CM code set, effective October 1, 2026, adds a dedicated category for medetomidine toxic effects (T65.85-). Before that, a hospital could treat a case and have nowhere to record it — so the national data everyone will cite in 2027 begins, for practical purposes, this fall.
The West is genuinely low-prevalence — but low is not zero. National Forensic Laboratory Information System data cited by the CDC put medetomidine at under 1% of all federal drug reports in 2025, concentrated in the Northeast. The more useful local detail: across 20 CDC-funded sentinel sites that tested drug products and paraphernalia from July through December 2025, all five Western sites — Alameda and Los Angeles counties in California, Public Health–Seattle & King County, Denver, and the Southern Nevada Health District — found medetomidine in their opioid-positive samples, at levels between 2% and 8%. San Diego is not one of those sentinel sites. A county that is not looking with a sensitive instrument will not find a drug that sits at 2%.
Syndromic surveillance sees what someone wrote down. It flags patterns in emergency department records. Where there is no specific code, no specific test, and a toxidrome that looks exactly like an opioid overdose, there is nothing distinctive to flag. The CDC recommends this surveillance for exactly this purpose; the county's advisory is the first instruction many local clinicians will have received to consider the drug at all.
None of this means the county's count is wrong. It means the count measures the instruments, not the supply. The drug was found by people who test drugs, not by people who fill out charts.
What it does in an overdose
The clinical picture in the advisory matches what hospitals in the Northeast and Midwest have reported for two years. Medetomidine causes marked bradycardia — the CDC documents heart rates as low as 32 beats per minute — along with hypotension and profound, often prolonged sedation. Combined with fentanyl, the effect on breathing is additive.
Two practical points follow. First, naloxone still goes in: of 995 drug product samples that tested positive for medetomidine between July and December 2025, 98% also contained fentanyl. Second, unlike xylazine, medetomidine does not appear to cause necrotizing wounds — so a person can be using a contaminated supply without the visible mark families have been taught to look for.
The largest documented cluster remains Chicago's in May 2024: 140 suspected medetomidine-involved overdoses, at least 16 people hospitalized and one death.
The withdrawal clock
Medetomidine withdrawal is what fills intensive care beds, and the advisory spells out the timeline for local clinicians. Symptoms can begin within hours of last use and peak 18 to 36 hours later: severe hypertension, heart rate above 100, chest pain, tremor, fluctuating alertness, and nausea and vomiting that will not settle. Severe cases have been complicated by non-ST elevation myocardial infarction and posterior reversible encephalopathy syndrome, and treatment can require a dexmedetomidine infusion in an emergency or intensive care setting.
The county's instruction to providers is to build withdrawal protocols now — "to ensure that patients are appropriately triaged to intensive or emergency care, when needed." That is a quiet acknowledgment that the clinical load arrives before the data does. We covered the hospital-side evidence in our September analysis of medetomidine withdrawal and ICU admissions; the short version for families: abrupt unsupervised withdrawal is not the safer choice, and chest pain, fainting, confusion or repeated vomiting are reasons to call 911, not to wait.
What to do this week in San Diego County
Test before you use, especially from a new source. The advisory directs people who use drugs to test with commercially available medetomidine strips, available through the County's Harm Reduction Services Program and syringe services programs. One caveat: the program's public page currently lists free fentanyl and xylazine strips, so call 2-1-1 to confirm what is stocked where. If a sample tests positive, the county's guidance is to use less or not at all.
Carry naloxone anyway, and carry two doses. Free naloxone comes through the County's Naloxone Distribution Program, by calling 2-1-1, or through the county's naloxone resource map; it is also sold over the counter. It will not reverse medetomidine sedation, and that is exactly why it still belongs in the kit — the fentanyl beside it will kill.
Do not use alone, and do not mix. A bystander is the only thing that closes the gap between an overdose and a rescue, and mixing depressants stacks the sedation.
If someone is unresponsive: give naloxone, call 911, support their breathing, and put them on their side. Tell responders what was used if you know. Expect that breathing may improve while the person stays asleep — that is the medetomidine, and it is a reason for a hospital, not a reason to wait.
Ask about medication for opioid use disorder. The advisory directs providers to connect people who use opioids with buprenorphine or methadone where appropriate. The county's Access and Crisis Line is (888) 724-7240, 24 hours a day.
For clinicians: the advisory asks for medetomidine-specific toxicology where it will change management, noting that samples go to a reference laboratory and may take days, and that testing decisions should be patient-specific per the American Society of Addiction Medicine's draft consensus statement.
What this does not mean
It does not mean San Diego County is in the middle of a medetomidine outbreak. The advisory reports no local death and no local cluster. It means the supply has changed in a way that is invisible to the systems built to watch it, and that the people most exposed are the ones least likely to be counted.
The county's framing is the right one: this is information for people who use drugs, for the people who love them, and for the clinicians who treat them. A test strip and a naloxone kit are what convert a warning into a survivable night.
Where to get help
- Emergency: Call 911. If someone is unresponsive or struggling to breathe, give naloxone and call immediately.
- 988 Suicide & Crisis Lifeline: Call or text 988, or chat at 988lifeline.org — 24/7, free, confidential.
- SAMHSA National Helpline: 1-800-662-4357 (1-800-662-HELP) — 24/7, free, confidential, English and Spanish.
- Find a treatment provider: FindTreatment.gov — opioid treatment programs, buprenorphine prescribers, sliding-scale options.
- San Diego County: 2-1-1 for naloxone, test strips and local services; Access and Crisis Line (888) 724-7240.
- Naloxone basics: our guides to getting naloxone and drug checking.
Sources
- CAHAN San Diego — Health Advisory: Medetomidine in the San Diego County Drug Supply (October 29, 2026)
- CAHAN San Diego — 2026 Alert Index, County of San Diego Health & Human Services Agency
- CDC Health Alert Network — Medetomidine in the U.S. Illegal Fentanyl Supply Increasing Risk for Overdose and Severe Withdrawal Syndrome (CDCHAN-00527, April 2, 2026)
- Center for Forensic Science Research & Education, NPS Discovery — Medetomidine Monograph
- IMO Health — Here's what's changing in the 2027 ICD-10-CM code set update
- County of San Diego — Harm Reduction Services Program
- County of San Diego Behavioral Health Services — About Naloxone
- CBS 8 / KFMB News 8 — New drug detected in San Diego County's illegal drug supply, prompting health warning (November 6, 2026, syndicated via Yahoo News)
- SAMHSA National Helpline
You might also read


